# (S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH

**Cat. No.:** HY-131168

**CAS No.:** 2086301-47-3

**Molecular Formula:** $C_{39}H_{58}N_6O_7S$

**Molecular Weight:** 754.98

**Target:** E3 Ligase Ligand-Linker Conjugates

**Pathway:** PROTAC

**Storage:** -20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 100 mg/mL (132.45 mM; Need ultrasonic)

| Preparing Stock Solutions | Mass / Solvent / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 1.3245 mL | 6.6227 mL | 13.2454 mL |
| | 5 mM | 0.2649 mL | 1.3245 mL | 2.6491 mL |
| | 10 mM | 0.1325 mL | 0.6623 mL | 1.3245 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 5.5 mg/mL (7.28 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 5.5 mg/mL (7.28 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (3.31 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

(S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH (VH032-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH) is a E3 ligase ligand-linker conjugate that contains on one end a VHL ligand. (S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH is used in PROTAC technology[1].

**$IC_{50}$ & Target**

VHL

**In Vitro**

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Yimin Qian, et al. Compounds and methods for the targeted degradation of bromodomain-containing proteins. WO2017030814A1.

[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-991.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA